Prothena Corporation plc (PRTA) Stock Grade

About Prothena Corporation plc's fundamentals

Prothena Corporation is a small-cap biotechnology company with a market capitalization of $514.1 million that reported a significant net loss in its latest annual statement, resulting in a net margin of -2520.6%. The company experienced severe revenue contraction, declining 92.8% year-over-year, indicating a substantial reduction in sales. With no dividend yield and negative profitability metrics, the company is not currently generating positive earnings or returning capital to shareholders. These metrics suggest Prothena is in a challenging financial position and is burning cash rather than generating profits.